DRL responds to notice on nitrogen leak

Image
B Krishna Mohan Chennai/ Hyderabad
Last Updated : Jan 20 2013 | 7:32 PM IST

The Director of Factories (DoF), the government agency overseeing the safety aspects at the factories, is likely to take up the matter related to the nitrogen gas leak at Dr Reddy's Laboratories here for prosecution next week, according to a senior DoF official.

The department recently received pharma major's reply to the showcause notice. "The report from the company has come. Some statutory procedures are to be done. They will be done by next week,'' the official told Business Standard. He declined to give the contents of the reply.

The government had issued a showcause notice asking the company to explain on the venting mechanism at the site of accident and sensor system, among others.

A chemist and a contract worker had died in the nitrogen gas leak last month at Unit III of Dr Reddy's Laboratories at Bollaram. The US Food and Drug Administration-approved plant produces active pharmaceutical ingredients. Access to the 'clean room' where the accident occurred continues to be restricted.

Pharma companies use nitrogen in areas where there is a possibility of sparks flying due to chemical reaction as the gas cuts down the oxygen availability.

The Factories Act (Section 104 A) puts the onus on the person (or the company) to prove that all practicable measures were taken. If found guilty, the punishment could be imprisonment for a term that might extend to two years or a fine of Rs 100,000 or both.

The DoF will also issue a circular giving out the technical specifications to all companies having similar process plants to ensure that similar accidents do not occur. The officials probing believe it to be the first accident of its kind that happened at a pharma unit involving nitrogen.

Also, the three-member committee set up to study whether the company adhered to safety standards is yet to submit its report. The committee comprises two officials from the DoF and a pharma expert. However, the DoF will not wait for the report to initiate action, if any, against the company. "The three-member committee will study various pharma-related processes at length where nitrogen is used,'' the official said, adding the report would take some more time.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 13 2011 | 12:25 AM IST

Next Story